Publications by authors named "A Pulsoni"
Background: The introduction of all- retinoic acid (ATRA) and arsenic trioxide (ATO) has radically improved the prognosis of acute promyelocytic leukemia (APL), with cure rates above 80%. While relapse occurs in less than 20% of cases, addressing this issue remains challenging. Identifying effective salvage therapies for relapsed APL is crucial to improve patient outcomes.
View Article and Find Full Text PDFLeucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.
Br J Haematol
November 2024
Article Synopsis
- ATRA and ATO are the main treatments for low to medium risk acute promyelocytic leukaemia (APL), but many patients (60%) can have a side effect called leucocytosis, which means very high white blood cell counts.
- Researchers studied 65 APL patients and found that those with lower levels of important blood proteins (like fibrinogen) and higher amounts of cancer cells in their bone marrow were more likely to have leucocytosis when treated with ATRA and ATO.
- Leucocytosis can lead to other serious problems, so doctors need to keep a close eye on patients with these risk factors to help prevent issues and give extra treatments if needed.
Mixed cryoglobulinemia vasculitis (MCV) is caused in ~90% of cases by chronic hepatitis C virus (HCVMCV) and more rarely by hepatitis B virus (HBV) infection, or apparently noninfectious. HCVMCV develops in only ~5% of patients with chronic hepatitis C (CHC), but risk factors other than female gender have not been identified so far. We conducted a retrospective case control study investigating whether past active HBV infection, defined by hepatitis B surface antigen (HBsAg) seroclearance and anti-core antibody (HBcAb) positivity, could be a risk factor for developing HCVMCV.
View Article and Find Full Text PDFArticle Synopsis
- This study looked at treating early-stage follicular lymphoma with radiation therapy and a medicine called ofatumumab.
- They treated patients first with radiation and then gave ofatumumab to those still having cancer traces in their blood.
- Out of the 110 people in the study, many improved after treatment, with some showing no signs of the disease for a long time.
Concern has emerged about the prevalence of second cancers among patients with hairy cell leukemia (HCL) treated with purine analogs. We investigated 513 patients with HCL treated with cladribine over the last 30 years at 18 Italian centers and calculated their standardized incidence ratios (SIRs). We identified 24 patients with a second cancer diagnosed at a median time from treatment with cladribine of 59.
View Article and Find Full Text PDF